Donald F. Weaver
Oprichter bij Treventis Corp.
Profiel
Donald F.
Weaver is the founder of DeNovaMed, Inc. (founded in 2006) and holds the title of Chief Medical Officer starting in 2013.
Dr. Weaver is also the founder of Neurochem (International) Ltd., Molecular Mining Corp., and Treventis Corp.
Dr. Weaver's current job is at Dalhousie University, where he holds the title of Professor.
Dr. Weaver's former job was at the Canada Research Chairs Program, where he held the title of Principal.
Actieve functies van Donald F. Weaver
| Bedrijven | Functie | Begin |
|---|---|---|
Treventis Corp.
 Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Oprichter | 07-04-2010 |
| Dalhousie University | Corporate Officer/Principal | - |
DeNovaMed, Inc.
 DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Oprichter | 01-01-2006 |
Neurochem (International) Ltd.
 Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Oprichter | - |
Eerdere bekende functies van Donald F. Weaver
| Bedrijven | Functie | Einde |
|---|---|---|
| Molecular Mining Corp. | Oprichter | 22-03-2013 |
| Canada Research Chairs Program | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Commercial Services |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Health Technology |
| Canada Research Chairs Program | Government |
| Molecular Mining Corp. | |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Health Technology |
